Approval · Notice of Compliance 24521 · 2020
IDACIO: Notice of Compliance 24521
Issued October 30, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 24521
- Date
- October 30, 2020
- Company
- Fresenius Kabi Canada LtdToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Canadian reference product
- HUMIRA
Products in this notice
Medicinal ingredients
- ADALIMUMAB 40 MG per SYR
- ADALIMUMAB 40 MG per PEN
- ADALIMUMAB 40 MG per VIAL